Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November.
The drug’s manufacturer, Novartis, said Sept. 29 it plans to launch a direct-to-patient platform on Nov. 1 for cash-paying U.S. patients. For a four-week supply, Cosentyx’s list price is $7,936 for a self-injection package and $4,401 per intravenous infusion, according to Novartis.
Cosentyx (secukinumab) is an FDA-approved biologic to treat six immune-mediated inflammatory diseases, including plaque psoriasis and psoriatic arthritis.
In 2024, hospitals, clinics, pharmacies and other healthcare facilities spent $7.7 billion on the medication, making it the 16th most expensive drug in healthcare.
Several other drugmakers have recently launched direct-to-consumer portals and other platforms that offer discounts to cash-paying patients, including Pfizer, Eli Lilly and Novo Nordisk.
